Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men

Doi, Masayuki; Miyoshi, Toru; Hirohata, Satoshi; Nakamura, Kazufumi; Usui, Shinichi; Takeda, Kazuki; Iwamoto, Mutsumi; Kusachi, Shozo; Kusano, Kengo; Ito, Hiroshi

doi:10.1186/1475-2840-10-44

Cited by 37 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, AFABP concentrations significantly increase with the number of stenotic coronary arteries [75]. In accordance with these findings, three independent studies have reported that serum AFABP is significantly elevated in patients with coronary artery disease (CAD) [76][77][78]. Very recently, a small casecontrol study detected significantly elevated serum AFABP levels in patients with cerebrovascular disease, whereas no difference was found in patients with CAD [79].…”

Section: Controlssupporting

confidence: 53%

“…Furthermore, murine adipocytes release various proteins lacking a secretory signal sequence by microvesicles and, most interestingly, AFABP is detected in microvesicles [64]. These findings are supported by an independent study that [73] 98 CAD Associated with MS + TG [74] 479 with carotid IMT Associated with IMT in women + Age, BP, carotid IMT (in women) [75] 234 with coronary angiograms Associated with CAD n.d. [76] 211 CAD ↑ in CAD + CAD 211 controls [77] 125 CAD ↑ in CAD + Plaque volume (CAD) 120 controls [78] 247 CAD ↑ in CAD + Coronary atherosclerosis index 94 controls [79] 18 CAD/CVD ↑ in CVD n.d. 18 controls [80] 87 controls Associated with vascular inflammation + Vascular inflammation [90] 306 acute ischaemic stroke ↑ in ischaemic stroke n.d.…”

Section: Circulating Afabp-a Potential Novel Adipokinementioning

confidence: 99%

See 1 more Smart Citation

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

2012

View full text Add to dashboard Cite

Adipocyte fatty acid binding protein (AFABP, also known as aP2 and FABP4) has recently been introduced as a novel fat-derived circulating protein. AFABP serum concentrations are positively correlated with markers of the metabolic syndrome and vascular disease in various cross-sectional and interventional studies. Furthermore, a small set of prospective studies indicates that high AFABP serum levels at baseline predict the risk for metabolic and vascular morbidity and mortality. Studies in Afabp (also known as Fabp4) knockout mice and AFABP inhibitortreated animals suggest that total AFABP promotes insulin resistance, hypertriacylglycerolaemia and atherosclerosis by ligand/ligand delivery, as well as ligand-independent mechanisms. In contrast, the pathophysiological significance of circulating AFABP and the mechanisms leading to its release remain to be established. The current review summarises recent findings on the regulation and potential role of AFABP in metabolic and vascular disease.

show abstract

Section: Controlssupporting

confidence: 53%

Section: Circulating Afabp-a Potential Novel Adipokinementioning

confidence: 99%

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

2012

View full text Add to dashboard Cite

show abstract

“…For instance, circulating FABP4 correlated positively with carotid intima-media thickness in Chinese women, 20 with atherosclerotic burden measured by intravascular ultrasound, 21 or with CAD in nonelderly Japanese men. 22 These discrepant findings between white and Asian populations on the association of circulating FABP4 with CAD might be partially explained by different genetic and environmental background. For instance, the prevalence of hypertension, hypercholesterolemia, or overweight and obesity is higher in whites than in Asians.…”

Section: Discussionmentioning

confidence: 96%

Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals

Reiser¹,

Klingenberg²,

Hof³

et al. 2015

ATVB

View full text Add to dashboard Cite

Objective— Blood-borne biomarkers reflecting atherosclerotic plaque burden have great potential to improve clinical management of atherosclerotic coronary artery disease and acute coronary syndrome (ACS). Approach and Results— Using data integration from gene expression profiling of coronary thrombi versus peripheral blood mononuclear cells and proteomic analysis of atherosclerotic plaque–derived secretomes versus healthy tissue secretomes, we identified fatty acid–binding protein 4 (FABP4) as a biomarker candidate for coronary artery disease. Its diagnostic and prognostic performance was validated in 3 different clinical settings: (1) in a cross-sectional cohort of patients with stable coronary artery disease, ACS, and healthy individuals (n=820), (2) in a nested case–control cohort of patients with ACS with 30-day follow-up (n=200), and (3) in a population-based nested case–control cohort of asymptomatic individuals with 5-year follow-up (n=414). Circulating FABP4 was marginally higher in patients with ST-segment–elevation myocardial infarction (24.9 ng/mL) compared with controls (23.4 ng/mL; P =0.01). However, elevated FABP4 was associated with adverse secondary cerebrovascular or cardiovascular events during 30-day follow-up after index ACS, independent of age, sex, renal function, and body mass index (odds ratio, 1.7; 95% confidence interval, 1.1–2.5; P =0.02). Circulating FABP4 predicted adverse events with similar prognostic performance as the GRACE in-hospital risk score or N-terminal pro–brain natriuretic peptide. Finally, no significant difference between baseline FABP4 was found in asymptomatic individuals with or without coronary events during 5-year follow-up. Conclusions— Circulating FABP4 may prove useful as a prognostic biomarker in risk stratification of patients with ACS.

show abstract

“…6,11-18 Notably, an increased plasma level of FABP4 was shown to be independently associated with the presence of coronary artery disease. 19, 20 Moreover, FABP4 has been found in human atherosclerotic plaques, and its presence was associated with the features of inflammatory and vulnerable plaques as high-risk phenotypes. 19,21 F atty acid-binding proteins (FABPs) are a family of intracellular lipid chaperones, approximately 14-15-kDa predominantly cytosolic proteins that can reversibly bind hydrophobic ligands such as saturated and unsaturated long-chain fatty acids.…”

mentioning

confidence: 99%

Circulating Fatty Acid-Binding Protein 4 Concentration Predicts the Progression of Carotid Atherosclerosis in a General Population Without Medication

Furuhashi

Yuda

Muranaka

et al. 2018

Circ J

View full text Add to dashboard Cite

Background: Fatty acid-binding protein 4 (FABP4), which is expressed in both adipocytes and macrophages, is secreted from the cells and acts as an adipokine. An elevated circulating FABP4 level is associated with insulin resistance and atherosclerosis. Methods and Results:We investigated the causative association between FABP4 level and progression of atherosclerosis in subjects of the Tanno-Sobetsu Study, a population-based cohort. In 281 subjects without medication (male/female: 109/172) in the year 2010 or 2013, the carotid intima-media thickness (CIMT) assessed using carotid ultrasonography was significantly correlated with age, adiposity, blood pressure, renal dysfunction and levels of cholesterol, triglycerides, fasting glucose, HbA1c and FABP4 (r=0.331, P<0.001). Multiple regression analysis demonstrated that age, sex and FABP4 concentration were independent predictors of CIMT. A total of 78 (male/female: 29/49) of the 156 subjects in 2010 underwent carotid ultrasonography again in 2013. The change in CIMT each year during that 3-year period (mean ± SD: 3.8±22.3 µm/year) was positively correlated with basal levels of highsensitivity C-reactive protein (hsCRP) (r=0.231, P=0.046) and FABP4 (r=0.267, P=0.018) in 2010. After adjustment for age, sex and hsCRP level, the basal FABP4 level was independently associated with the change in CIMT per year.Conclusions: FABP4 concentration is an independent predictor of the progression of carotid atherosclerosis.

show abstract

Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men

Cited by 37 publications

References 31 publications

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals

Circulating Fatty Acid-Binding Protein 4 Concentration Predicts the Progression of Carotid Atherosclerosis in a General Population Without Medication

Contact Info

Product

Resources

About